BioSpace News Archive

Venatorx Pharmaceuticals announced expansion of its leadership team with three key industry veterans: Jason Burdette joining as Senior Vice President, CMC and Technical Operations: Armand Girard as Chief Business Officer; and Tamra Adams, and Chief Financial Officer.

Fortress Biotech, Inc. today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at the 36th Annual ROTH Conference on Monday, March 18, 2024, at 2:00 p.m. PT.

Tenax Therapeutics, Inc. today announced that it will participate in the 36th Annual Roth Conference in Dana Point, California, from March 17-19, 2024.

IceCure Medical Ltd., developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced it has received a Notice of Allowance from the Japan Patent Office for its patent application titled “Cryogen Flow Control”.

Cencora, Inc. announced that Steven H. Collis will retire as President and Chief Executive Officer of the Company and transition to the role of Executive Chair of the Cencora Board of Directors, effective October 1, 2024.

Lamassu Bio Inc. has been awarded a grant from the National Institutes of Health and National Cancer Institute for the development of their groundbreaking treatment for p53 wild-type sarcomas.

The Leukemia & Lymphoma Society announced that BeiGene, Ltd., a global oncology company, has signed a three-year partnership to join LLS as the National Presenting Sponsor of Survivorship & Hope at Light The Night philanthropic events across the U.S. helping to support blood cancer patients and families who have emerged from the darkness of cancer.

T2 Biosystems, Inc. today announced that the Nasdaq Hearings Panel has granted the Company’s request for continued listing on the Nasdaq Stock Market.

GV20 Therapeutics announced today that it has joined NVIDIA Inception, a program that nurtures startups revolutionizing industries with technological advancements.

Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), today reported promising interim results from its study on MB-204